Frequency of Multi-Drug-Resistant Pseudomonas Aeruginosa Infection in Patients with Bronchiectasis
Keywords:
Bronchiectasis, Hospitalization, Multi-Drug Resistant Pseudomonas Aeruginosa, TreatmentAbstract
To determine the frequency of multi-drug-resistant Pseudomonas aeruginosa (MDR-PA) in patients with bronchiectasis. Bronchiectasis is a chronic lung disorder that generally results in recurrent infections, and multidrug-resistant Pseudomonas aeruginosa (MDR-PA) represents an important challenge for clinicians. Treatment of such ventral hernia with MDR-PA becomes complex and is associated with significant morbidity, leading to a higher healthcare burden. The frequency of MDR-PA has not been precisely determined in patients with bronchiectasis, and such data will be essential to guide this study. A descriptive cross-sectional study was conducted from February 2024 to July 2024 in the Pulmonology Department of Gulab Devi Hospital, Lahore, aiming to investigate the prevalence of multi-drug-resistant Pseudomonas aeruginosa (PA-MDR) among bronchiectasis patients. Data collection included demographics, clinical symptoms, and microbiological analyses of sputum/bronchoalveolar lavage samples. Statistical analysis was performed using SPSS, employing descriptive statistics and chi-square tests to explore associations with PA-MDR status, with a level of significance 0.05.
Downloads
References
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al.
European respiratory society guidelines for the management of adult bronchiectasis. Eur
Respir J. 2017;50(3):1700629.
Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn JS, Floto RA, et al. British thoracic
society guideline for bronchiectasis in adults. BMJ Open Respir Res. 2018;5(1):e000348.
Chotirmall SH, Chalmers JD. Bronchiectasis: the forgotten worldwide epidemic. BMC
Pulm Med. 2018;18(1):76.
Contarini M, Finch S, Chalmers JD. Bronchiectasis: a case-based approach to investigation
and management. Eur Respir Rev. 2018;27(149):180016.
Chandrasekaran R, Mac Aogain M, Chalmers JD, Elborn SJ, Chotirmall SH. Geographic
variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm
Med. 2018;18(1):83.
Visser SK, Bye P, Morgan L. Management of bronchiectasis in adults. Med J Aust. 2018;
(4):177-83.
Araujo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, et al. The
independent contribution of pseudomonas aeruginosa infection to long-term clinical
outcomes in bronchiectasis. Eur Respir J. 2018;51(2):1701953.
Martinez-Garcia MA. Pseudomonas aeruginosa infection and exacerbations in
bronchiectasis: more questions than answers. Eur Respir J. 2018;51(2):1702497.
Wang H, Ji XB, Mao B, Li CW, Lu HW, Xu JF. Pseudomonas aeruginosa isolation in
patients with non-cystic fibrosis bronchiectasis: a retrospective study. BMJ Open. 2018;8
(3):e014613.
Koser U, Hill A. What's new in the management of adult bronchiectasis? F1000Res. 2017;
:527.
Lucca F, Guarnieri M, Ros M, Muffato G, Rigoli R, Da Dalt L. Antibiotic resistance
evolution of pseudomonas aeruginosa in cystic fibrosis patients (2010-2013). Clin Respir
J. 2018;12(7):2189-96.
Rodrigo-Troyano A, Melo V, Marcos PJ, Laserna E, Peiro M, Suarez-Cuartin G, et al.
Pseudomonas aeruginosa in chronic obstructive pulmonary disease patients with frequent
hospitalized exacerbations: a prospective multicentre study. Respiration. 2018;96(5):417-
Gao YH, Guan WJ, Zhu YN, Chen RC, Zhang GJ. Antibiotic-resistant pseudomonas
aeruginosa infection in patients with bronchiectasis: prevalence, risk factors and prognostic
implications. Int J Chron Obstruct Pulmon Dis. 2018;13:237-46.
McDonnell MJ, Jary HR, Perry A, MacFarlane JG, Hester KL, Small T, et al. Non-cystic
fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of
pseudomonas persistence and resistance. Respir Med. 2015;109(6):716-26.
McGuinness G, Naidich DP. CT of airways disease and bronchiectasis. Radiol Clin North
Am. 2002;40:1–19.
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of
bronchiectasis. Clin Pulm Med. 2005;4:205–9.
O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation
of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax.
;55:635–42.
Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, et al.
A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial
infection. N Engl J Med. 1996;335:1941–9.
Larche MJ. A short review of the pathogenesis of Sjogren’s syndrome. Autoimmun Rev.
;5:132–5.
Riu M, Chiarello P, Terradas R, Sala M, Garcia-Alzorriz E, Castells X, et al. Cost
attributable to nosocomial bacteremia. analysis according to microorganism and
antimicrobial sensitivity in a university hospital in Barcelona. Plos One. 2016;11(4):
e0153076.
Ding F, Han L, Xue Y, Yang IT, Fan X, Tang R, et al. Multidrug-resistant Pseudomonas
aeruginosa is predisposed to lasR mutation through up-regulated activity of efflux pumps
in non-cystic fibrosis bronchiectasis patients. Front Cell Infect Microbiol. 2022;12:934439.
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
